Excerpt ABVC Biopharma, Inc. a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). Article Summary If the submission is received, HREC approval will lead to a Clinical Trial Notification (CTN) submission to...